Home » Stocks » Lyra Therapeutics

Lyra Therapeutics, Inc. (LYRA)

Stock Price: $11.93 USD 0.24 (2.05%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed
After-hours: $11.93 +0.00 (0.02%) Sep 18, 4:29 PM

Stock Price Chart

Key Info

Market Cap 154.19M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 12.92M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 18, 2020
Last Price $11.93
Previous Close $11.69
Change ($) 0.24
Change (%) 2.05%
Day's Open 11.79
Day's Range 11.50 - 11.94
Day's Volume 28,957
52-Week Range 10.44 - 22.00

More Stats

Market Cap 154.19M
Enterprise Value 70.16M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 12.92M
Float 7.24M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 451,273
Short Ratio 3.18
Short % of Float 2.85%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.73
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 84.03M
Net Cash / Share 6.50
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -51.21%
ROE -106.55%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$23.67*
(98.41% upside)
Low
19.0
Current: $11.93
High
28.0
Target: 23.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue-1.24
Gross Profit-1.24
Operating Income-16.52-7.26
Net Income-16.31-6.03
Shares Outstanding0.200.17
Earnings Per Share-82.23-36.79
Operating Cash Flow-13.75-6.64
Capital Expenditures-0.21-0.04
Free Cash Flow-13.97-6.68
Cash & Equivalents10.1424.22
Total Debt3.33-
Net Cash / Debt6.8124.22
Assets14.9625.36
Liabilities7.642.08
Book Value-123-107
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Lyra Therapeutics, Inc.
Country United States
Employees 31
CEO Maria Palasis

Stock Information

Ticker Symbol LYRA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LYRA
IPO Date May 1, 2020

Description

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts. Address: 480 Arsenal Way, Watertown, MA, United States, 02472